Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Shares Outstanding (Diluted Average) (2016 - 2025)

Northwest Biotherapeutics' Shares Outstanding (Diluted Average) history spans 15 years, with the latest figure at $1.5 billion for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $1.5 billion for Q4 2025, up 17.26% from a year ago — trailing twelve months through Dec 2025 was $1.5 billion (up 17.26% YoY), and the annual figure for FY2025 was $1.5 billion, up 17.26%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $1.5 billion at Northwest Biotherapeutics, up from $1.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $1.5 billion in Q4 2025 to a low of $834605.0 in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $1.1 million (2021), against an average of $136.0 million.
  • The sharpest move saw Shares Outstanding (Diluted Average) decreased 12.5% in 2022, then surged 110894.19% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $1.0 million in 2021, then rose by 0.79% to $1.0 million in 2022, then rose by 10.17% to $1.1 million in 2023, then surged by 110894.19% to $1.2 billion in 2024, then increased by 17.26% to $1.5 billion in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $1.5 billion, $1.5 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.